Merck(US:MRK) 仪器信息网·2025-09-26 09:15Core Viewpoint - Merck has appointed Kai Beckmann as the new CEO, set to officially take over from Belén Garijo on May 1, 2026, ensuring a smooth transition while Garijo continues in her role until the end of her term [1][4]. Group 1: Leadership Transition - Belén Garijo has been with Merck for 15 years, leading the pharmaceutical and healthcare business for six years and serving as CEO since 2021. Her key achievements include navigating the company through the COVID-19 pandemic and geopolitical challenges, as well as optimizing the business structure through strategic acquisitions and divestitures [4][5]. - Garijo will continue to focus on the pharmaceutical and healthcare sectors after her tenure, emphasizing her commitment to meeting patient needs [4][5]. - Kai Beckmann has been a member of Merck's executive board since 2011 and has led the high-performance materials business, transforming it into a core enabler in the global semiconductor industry [5][6]. Group 2: Future Outlook - Johannes Bailou, Chairman of the Executive Board and Family Board, highlighted Garijo's leadership in restoring profitability and shaping Merck into a global technology leader. He expressed confidence in Beckmann's vision for technological transformation, which is expected to create significant value for patients, customers, and society [5][6]. - Beckmann's extensive experience in local and global markets is seen as crucial for opening a new chapter for the group, ensuring continuity and normal operations during the transition [5].